Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.
The U.S. Food and Drug Administration (FDA) approved Empaveli on
Q: Where did you grow up?
I grew up in Scranton and Mechanicsburg, Pennsylvania and regularly traveled from Pittsburgh to Philly. My mom was a registered nurse, and I would volunteer to assist her growing up. Caring for her patients not only ignited my philanthropic passion but also illuminated the many bumps on their road to recovery. I
…
An upstate New York health center has sued the nation’s four major insulin manufacturers for allegedly conspiring to stop offering 340B pricing when covered entities use contract pharmacies.
Mosaic Health’s July 30 lawsuit claims that insulin manufacturers’ Sanofi, Eli
…
Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.
BI this morning confirmed that it has begun denying 340B pricing
…
340B covered entities dodged a bullet Sunday when U.S. Senate negotiators released the text of a $550 billion bipartisan infrastructure-spending bill. It did not contain Medicaid managed care “spread pricing” language that entities have been fending off since 2019. Entities
…
A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.
Federal spending legislation that President Trump signed into law last Dec. 27 included a
…
×
*Sign up for news summaries and alerts from 340B Report
